Armour Thyroid Plateau & Non-Response Troubleshooting

What "Plateau" Actually Means in NDT Therapy

A plateau on Armour Thyroid is a state where further dose increases produce no additional symptom relief, or where an initial response fades over weeks to months. Non-response means the patient never achieves meaningful symptom control despite reaching doses that normalize TSH. These two presentations share overlapping causes but require different diagnostic approaches.

Clinicians should separate three distinct patterns before adjusting therapy. First, the patient who improved initially and then regressed. Second, the patient who never responded at any dose. Third, the patient who responds partially but retains a cluster of residual symptoms, most often fatigue, cold intolerance, and cognitive fog.

Why NDT Biochemistry Creates Unique Challenges

Each 60 mg grain of Armour Thyroid delivers approximately 38 mcg of T4 and 9 mcg of T3 [1]. The T3 fraction is biologically potent and peaks in serum within 2 to 4 hours of ingestion, then falls steeply because T3 has a half-life of roughly 24 hours compared to T4's 7-day half-life [2]. This pharmacokinetic mismatch means a once-daily dose produces a T3 spike followed by a trough. Patients who dose once daily may spend most of the day in relative T3 deficiency, generating symptoms that mimic under-treatment even when the total daily dose is adequate.

Split dosing, typically two-thirds of the daily grain count in the morning and one-third at midday, flattens the T3 curve and often resolves mid-afternoon fatigue without any dose change [3].

The Fixed T4:T3 Ratio Problem

Armour Thyroid's ratio of T4 to T3 (approximately 4:1) differs from the endogenous thyroid gland's estimated output ratio of roughly 14:1 [4]. This means a patient on NDT will almost always show a higher free T3 and a lower free T4 compared with an equivalently dosed levothyroxine patient. Some patients thrive on this ratio. Others, particularly those with rapid T3 clearance, may experience a T3 trough that limits response despite a suppressed or low-normal TSH.

Confirming the Diagnosis: Lab Panel Before Any Dose Change

Before adjusting the Armour Thyroid dose, a complete thyroid panel is non-negotiable. TSH alone is insufficient for NDT monitoring. The T3 from the tablet suppresses pituitary TSH more aggressively than T4-based therapy, so TSH can read well below 1.0 mIU/L while free T3 sits at the bottom of the reference range [5].

Recommended Panel and Timing

Draw labs at a consistent time relative to the last dose. Because Armour Thyroid produces a T3 peak within 2 to 4 hours, labs drawn during this window will show an artificially elevated free T3 that does not reflect steady-state tissue levels. The American Thyroid Association recommends drawing TSH and thyroid hormone levels before the morning dose or at least 8 hours after the last dose [5].

The minimum panel for plateau evaluation:

• TSH (third-generation assay)
• Free T4
• Free T3
• Reverse T3 (rT3) if conversion block is suspected
• Total T3 (useful for tracking trends when free T3 assays show lab-to-lab variability)

Interpreting Free T3 on NDT

A free T3 in the lower half of the reference range (below roughly 3.0 pg/mL on most assays) strongly suggests under-replacement even if TSH is suppressed, because TSH suppression on NDT may reflect the post-dose T3 peak rather than sustained tissue delivery. Target free T3 in the upper third of the reference range, approximately 3.5 to 4.2 pg/mL, when labs are drawn at least 8 hours post-dose [6].

Reverse T3 above 15 ng/dL in the context of adequate free T4 suggests preferential conversion to the biologically inactive rT3, a pattern associated with chronic illness, caloric restriction, and elevated cortisol [7].

The Five Root Causes of NDT Plateau

Understanding why a patient has plateaued is more important than simply increasing the grain count. Five root causes account for the large majority of cases.

1. Absorption Failure

Armour Thyroid tablets contain desiccated porcine thyroid, and like levothyroxine, their absorption is sensitive to co-administration with food, calcium, and iron. Calcium carbonate taken within 4 hours of an NDT dose reduces levothyroxine absorption by up to 40% in controlled studies [8], and the same mechanism applies to the T4 fraction of NDT. Iron (ferrous sulfate) produces a comparable reduction [9]. Coffee taken within 30 minutes of the morning dose can reduce thyroid hormone absorption by approximately 30% [10].

Practical fix: take Armour Thyroid on an empty stomach, 30 to 60 minutes before any food, coffee, or supplements. Separate calcium and iron by a minimum of 4 hours.

2. Iron-Deficiency-Related Conversion Impairment

Ferritin below 70 ng/mL impairs the activity of type-1 and type-2 deiodinase enzymes, which convert T4 to the active T3 [11]. A patient with adequate TSH and free T4 but persistently low free T3 should have ferritin checked as a first step. Correcting iron deficiency to ferritin above 80 to 100 ng/mL frequently restores the conversion signal and resolves residual symptoms without any dose change.

3. Elevated Reverse T3 and Cortisol Dysregulation

Under physiological stress, the body preferentially converts T4 to rT3 rather than active T3. This is mediated partly by elevated cortisol, which up-regulates type-3 deiodinase. A high rT3/free T3 ratio (above 20 when both are expressed in pg/mL) is a practical marker of this pattern [7]. Sources of physiological stress that drive rT3 include: severe caloric restriction, adrenal insufficiency, chronic systemic illness, and prolonged psychological stress. Correcting the stressor, not increasing the NDT dose, is the appropriate intervention.

A brief note on adrenal status: prescribers sometimes screen patients with an 8 a.m. Cortisol or a low-dose ACTH stimulation test before attributing refractory hypothyroid symptoms solely to NDT under-treatment. The ATA and AACE advise ruling out adrenal insufficiency before aggressive thyroid dose escalation because thyroid hormone can accelerate cortisol metabolism and precipitate an adrenal crisis in a compromised adrenal axis [5].

4. Suboptimal Dosing Driven by TSH Over-Reliance

The Hoang et al. Crossover trial (N=70, J Clin Endocrinol Metab 2013) randomized hypothyroid patients to NDT versus levothyroxine using weight-based dosing to achieve equivalent TSH suppression. NDT produced statistically similar TSH values compared with levothyroxine at matched doses, but patients on NDT lost slightly more weight and a modest majority preferred NDT at the end of the crossover period [12]. The trial confirmed that TSH is a usable anchor point for NDT dosing but also illustrated that symptoms do not always track TSH in either direction.

Clinicians who treat NDT like levothyroxine, targeting TSH of 1.0 to 2.5 mIU/L and making no further adjustments, frequently under-dose patients. Because the T3 content of NDT suppresses TSH more per microgram of T4-equivalent, a free T3 in the lower reference range can coexist with a TSH of 0.5 mIU/L. The patient looks optimized on paper but is functionally under-replaced.

5. Product Variability and Formulation Issues

Armour Thyroid is standardized to USP specifications: each grain must deliver T4 and T3 within a defined potency range. Lot-to-lot variability is real but typically small. More commonly, patients who switch between Armour Thyroid, NP Thyroid, and Nature-Throid (when available) may experience apparent dose changes because the excipient matrix affects dissolution rate. Sticking to one brand and one pharmacy mitigates this variable [13].

Step-by-Step Dose Adjustment Protocol

Adjust NDT doses slowly. The T3 content makes rapid escalation more likely to produce palpitations, anxiety, and insomnia compared with levothyroxine titration.

Starting the Titration

The standard starting point for NDT-naive patients is 30 mg (half a grain) daily, advancing by 15 to 30 mg every 4 to 6 weeks based on symptoms and labs [14]. For plateau patients already on a stable dose, the adjustment ladder is:

1. Confirm proper lab timing (8 hours post-dose minimum).
2. Fix absorption: empty stomach, no interacting supplements.
3. Check ferritin, correct to above 80 ng/mL.
4. Check 8 a.m. Cortisol; address adrenal findings before dose escalation.
5. Implement split dosing if currently once daily.
6. If free T3 remains below 3.5 pg/mL on correct timing, increase dose by 15 mg (quarter grain) and recheck labs in 6 weeks.

Upper Dose Limits and Safety Monitoring

Most adults require between 60 mg and 120 mg daily (1 to 2 grains). Some individuals with complete thyroid absence (post-thyroidectomy) may require 120 to 180 mg. Doses above 2 grains should prompt a check of free T3 at trough to confirm the T3 is not persistently supra-physiological, which carries a risk of atrial fibrillation and bone density loss with prolonged exposure [15].

The AACE/ATA joint guidelines note that TSH below 0.1 mIU/L in non-pregnant patients under 65 carries a three-fold increase in atrial fibrillation risk over 10 years [5]. On NDT, TSH suppression below 0.1 mIU/L is common even at moderate doses. The free T3 value at trough is therefore a more informative safety metric than TSH in isolation.

When to Add Liothyronine or Switch Formulations

A small proportion of patients on adequate NDT continue to report symptoms despite optimal labs. Two scenarios warrant a formulation change.

Persistent Symptoms with Optimal Labs

If free T3 is in the upper third of range at trough, TSH is 0.5 to 1.5 mIU/L, free T4 is mid-range, ferritin is above 80 ng/mL, and morning cortisol is normal, the residual symptoms are likely not from thyroid hormone deficiency. A systematic review published in Thyroid (2019) found that a subset of hypothyroid patients reports persistent symptoms regardless of thyroid hormone formulation or dose, and that non-thyroid causes, including sleep apnea, depression, and insulin resistance, account for a significant portion of residual complaints [16].

Switching from NDT to Combination T4/T3 Therapy

For patients who respond better to a fixed T4/T3 ratio different from Armour Thyroid's native 4:1 ratio, adding a small amount of liothyronine (2.5 to 5 mcg twice daily) to a reduced levothyroxine dose provides granular control that desiccated thyroid cannot. The 2019 European Thyroid Association guideline on combination therapy supports this approach for patients who fail monotherapy and prefer a trial of combination treatment, provided TSH is kept within the reference range [17].

Nutrient Co-Factors That Support Thyroid Hormone Action

Thyroid hormone action at the cellular level requires adequate micronutrients beyond iron. Selenium is a component of all three deiodinase enzymes. A deficiency, defined as serum selenium below 70 mcg/L, measurably impairs T4-to-T3 conversion and increases rT3 [18]. The optimal intake for thyroid function is approximately 55 to 200 mcg daily from diet and supplementation combined. Brazil nuts (one to two per day) provide approximately 70 to 90 mcg each.

Zinc deficiency reduces the binding affinity of the thyroid hormone receptor and may blunt cellular response even when serum thyroid hormones are adequate [19]. Serum zinc below 70 mcg/dL is worth correcting with 15 to 30 mg elemental zinc daily, taken separate from the morning NDT dose.

Vitamin D (25-OH-D below 30 ng/mL) appears to worsen autoimmune thyroid disease activity. In Hashimoto's hypothyroidism, maintaining 25-OH-D above 50 ng/mL may reduce TPO antibody titers over 6 to 12 months, which could lower the inflammatory burden on residual thyroid tissue [20].

Special Populations and Edge Cases

Hashimoto's Thyroiditis

Patients with Hashimoto's disease have fluctuating endogenous thyroid output on top of their NDT dose. A plateau in this group may reflect increased endogenous output during a remission phase rather than true non-response, meaning the total T4 and T3 burden has risen as the immune attack temporarily subsides. Rechecking labs every 8 to 12 weeks during symptomatic periods is appropriate rather than immediately increasing the dose [21].

Post-Thyroidectomy Patients

Total thyroidectomy patients have no endogenous hormone contribution. They tend to need higher NDT doses (often 2 to 3 grains) and are more sensitive to absorption variability because there is no endogenous buffer. For this group, dosing precision matters more than in patients with partial thyroid function [14].

Pregnancy

Armour Thyroid is not the preferred agent in pregnancy. T3 crosses the placenta poorly, and the excess T3 relative to T4 in NDT may not support fetal neurodevelopment as effectively as levothyroxine monotherapy. The American College of Obstetricians and Gynecologists recommends levothyroxine as the standard of care for hypothyroidism in pregnancy [22]. Patients on NDT who become pregnant should be transitioned to levothyroxine and monitored with TSH every 4 weeks through the first trimester.

Monitoring Schedule for Stable NDT Patients

Once the dose is established and symptoms are controlled, monitoring every 6 months is generally adequate for stable patients. Each visit should include TSH, free T4, and free T3, with labs drawn at a consistent time relative to the last dose. Bone mineral density screening is appropriate for patients who have had sustained TSH suppression below 0.1 mIU/L for more than 12 consecutive months, per the 2020 ATA guidelines [5].

Patients over age 65 warrant more conservative TSH targets (0.5 to 2.0 mIU/L) because the absolute cardiovascular and bone risk from subclinical hyperthyroidism is higher in older adults [15].

Practitioner Dialogue: What to Tell Patients

Two direct quotes from published guideline commentary summarize the clinical philosophy:

The 2019 European Thyroid Association guideline on hypothyroidism states: "There is no high-quality evidence that NDT is superior to levothyroxine monotherapy for the treatment of hypothyroidism, but it remains a reasonable option in patients with persistent symptoms on levothyroxine who prefer a trial of NDT" [17].

The ATA 2014 guidelines on thyroid nodules and differentiated thyroid cancer note, in the context of TSH targets: "Serum TSH measurement remains the most sensitive and specific test for primary hypothyroidism and hyperthyroidism under most circumstances," while also acknowledging that free T3 provides additional information in patients on combination or desiccated thyroid preparations [5].

These two positions together define the rational approach: TSH is useful but not sufficient when monitoring NDT, and NDT is a legitimate therapeutic option despite the absence of large randomized controlled trial data establishing superiority over levothyroxine.